Arbutus Biopharma (ABUS) Stock: Buy, Sell, or Hold?
ABUS - Arbutus Biopharma Corporation Common Stock
$4.45
-0.11 (-2.41%)
▼
5d:
-8.25%
30d:
-12.75%
90d:
-10.46%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 22, 2026 at $5.00 · last confirmed Oct 1, 2026
Strength: 9.0/10
Get Alerted When ABUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ABUS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ABUS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABUS is currently trading at $4.45, which is considered oversold relative to its 30-day fair value range of $4.82 to $5.20.
Technical Outlook: Technically, ABUS is showing support break momentum. The price is currently testing key support at $4.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABUS scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.36 (+20.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABUS is showing support break momentum. The price is currently testing key support at $4.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABUS scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.36 (+20.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.82 -
$5.20
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
Protect Your Profits
Holding ABUS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.4% below Wall St target ($5.36)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.82 -
$5.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.38
Resistance Level
$5.07
Current Trend
Support Break
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-40.09
Wall Street Target
$5.36
(+20.4%)
Revenue Growth (YoY)
-90.6%
Profit Margin
84.2%
Share & Embed Analysis
Last updated: October 04, 2026 8:39 AM ET
Data refreshes hourly during market hours. Next update: 9:39 AM
Data refreshes hourly during market hours. Next update: 9:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
Advanced ABUS Option Strategies
Professional options setups generated by AI based on today's ABUS price and gamma walls.
